medigraphic.com
ISSN 1561-3011 (Digital)

2019, Número 4

<< Anterior Siguiente >>

Rev Cubana Invest Bioméd 2019; 38 (4)


Ácido úrico en la disfunción endotelial y la insulinorresistencia en la enfermedad cardiovascular

Céspedes MEM, Rodríguez GR, Suárez CN

Idioma: Español
Referencias bibliográficas: 58
Paginas: 1-17
Archivo PDF: 368.54 Kb.


RESUMEN

La determinación de la concentración de ácido úrico se realiza con frecuencia en los servicios de salud. Los niveles plasmáticos de ácido úrico se han asociado con las enfermedades cardiovasculares, y con sus factores de riesgo. Sin embargo, la relevancia de esta asociación aún es controvertida, razón por la que se propone fundamentar la relación entre el ácido úrico, el estrés oxidativo y mecanismos involucrados en la enfermedad cardiovascular. Se realizó la búsqueda de la información mediante las bases de datos de diferentes buscadores (Medline-PubMed, Cochrane, Scielo). La hiperuricemia estimula la producción de especies reactivas oxidantes intracelulares y la reacción del ácido úrico con el óxido nítrico se relaciona con la disfunción endotelial y la resistencia a la insulina. Los niveles de ácido úrico se asocian con la hipertensión arterial, la diabetes mellitus, el síndrome metabólico y la enfermedad cardiovascular. Se considera además, que el ácido úrico es un factor de riesgo independiente para eventos cardiovasculares y un predictor de la morbilidad y la mortalidad por estas enfermedades, aunque se requiere de estudios de intervención con hipouricémicos o uricosúricos para el análisis de los beneficios que pudiera representar modificar la concentración de ácido úrico en sangre en determinadas condiciones.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Anuario Estadístico de Salud 2018. Dirección Nacional de Registros Médicos y Estadísticas de Salud. MINSAP. La Habana; 2019.

  2. Sies H. Hydrogen peroxide as a central redox signaling molecule in physiological oxidative stress: Oxidative eustress. Redox Biol. 2017;11:613-9.

  3. Jamwal S, Sharma S. Vascular endothelium dysfunction: a conservative target in metabolic disorders. Inflammation Dis. 2018 acceso 03/04/2018;67(5):391-405. Available from: https://link.springer.com/content/pdf/10.1007%2Fs00011-018-1129-8.pdf

  4. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an anti-oxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA. 1981;78:6858-62.

  5. Huang Z, Hong Q, Zhang X, Xiao W, Wang L, Cui1 S, et al. Aldose reductase mediates endothelial cell dysfunction induced by high uric acid concentrations. Cell Comm Signal. 2017;15:3-16.

  6. Zhi L, Yuzhang Z, Tianliang H, Hisatome I, Yamamoto T, Jidong C, et al. High uric acid induces insulin resistance in cardiomyocytes in vitro and in vivo. PLoS ONE. 2016;11(2):e0147737. doi:10.1371/journal.pone.0147737

  7. Zhang D, Zhang R, Wang N, Lin L, Yu B. Correlation of serum uric acid levels with nonculprit plaque instability in patients with acute coronary syndromes: A 3-vessel optical coherence tomography study. BioMed Res Internat. 2018 acceso 03/04/2018;2018:7919165. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5820670/pdf/BMRI2018-7919165.pdf

  8. Martínez E, Tugores A, Rodríguez F. Serum uric acid levels and cardiovascular disease: the Gordian knot. J Thorac Dis. 2016;8(11):1462-6.

  9. Scheepers LEJM, Boonen A, Dagnelie PC, Schram MT, van der Kallen CJH, Henry RMA, et al. Uric acid and blood pressure: exploring the role of uric acid production in The Maastricht Study. J Hypertens. 2017;35(10):1968-75.

  10. Chen C, Lü JM, Yao Q. Hyperuricemia related disease and xanthine oxidorreductase inhibitors. An overview. Med Sci Monit. 2016;22:2501-12.

  11. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA. 2000;283(18):2404-10.

  12. Wang J, Tan GJ, Han LN, Bai YY, He M, Liu HB, et al. Novel biomarkers for cardiovascular risk prediction. J Geriatr Cardiol. 2017;14(2):135-50

  13. Whayne TF. Non-traditional cardiovascular risk markers in the era of established major risk factors and multiple guidelines. Curr Vasc Pharmacol. 2018; doi: 10.2174/1570161116666180123112956.

  14. Mandal AK, Mount DB. The molecular physiology of uric acid homeostasis. Annu Rev Physiol. 2015;77:323-45.

  15. Lima WG, Soares ME, Chaves VE. Uuric acid as a modulator of glucose and lipid metabolism. Biochimie. 2015;116.17-23.

  16. Cho SK, Kim S, Chung JY, Jee SH. Discovery of URAT1 SNPs and association between serum uric acid levels and URAT1. BMJ Open 2015;5:e009360. doi:10.1136/bmjopen-2015-009360

  17. Halliwell B. The antioxidant paradox: less paradoxical now? Br J Clin Pharmacol. 2012;75(3):637-44.

  18. Ferrer-Sueta G, Campolo N, Trujillo M, Bartesaghi S, Carballal S, Romero N, et al. Biochemistry of peroxynitrite and protein tyrosine nitration. Chem Rev. 2018;118(3):1338-408.

  19. Sevanian A, Davies KJ, Hochstein P. Serum urate as an antioxidant for ascorbic acid. Am J Clin Nutr. 1991;54(6 Suppl):1129S-34S.

  20. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359:1811-21.

  21. Gersch C, Palii SP, Imaram W, Kim KM, Karumanchi SA, Angerhofer A, et al. Reactions of peroxynitrite with uric acid: formation of reactive intermediates, alkylated products and triuret, and in vivo production of triuret under conditions of oxidative stress. Nucleosides Nucleotides Nucleic Acids. 2009;28(2):118-49.

  22. Park JH, Jin YM, Hwang S, Cho DH, Kang DH, Jo I, et al. Uric acid attenuates nitric oxide production by decreasing the interaction between endothelial nitric oxide synthase and calmodulin in human umbilical vein endothelial cells: a mechanism for uric acid-induced cardiovascular disease development. Nitric Oxide. 2013;32:36-42.

  23. Li P, Zhang L, Zhang M, Zhou C, Lin N. Uric acid enhances PKC-dependent eNOS phosphorylation and mediates cellular ER stress: a mechanism for uric acid-induced endothelial dysfunction. Internat J Molec Medic. 2016;37:989-97.

  24. Kuwabara M, Niwa K, Nishi Y. Relationship between serum uric acid levels and hypertension among Japanese individuals not treated for hyperuricemia and hypertension. Hypertens Res. 2014;37:785-9.

  25. Kuwabara M, Hisatome I, Niwa K, Hara S, Roncal-Jimenez CA, Bjornstad P, et al. Uric acid is a strong risk marker for developing hypertension from prehypertension: a 5-year Japanese cohort study. Hypertension. 2018;71:78-86.

  26. Chen Q, Yin YJ, Chen WY, Wu JN, Huang X. Assessment of the association between serum uric acid levels and the incidence of hypertension in nonmetabolic syndrome subjects: A prospective observational study. Medicine (Baltimore). 2018 citado 2018 Abr 02;97(6):e9765. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944703/pdf/medi-97-e9765.pdf 97(6):e9765. doi: 10.1097/MD.0000000000009765.

  27. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300:924-32

  28. Agarwal V, Hans N, Messerli FH. Effect of allopurinol on blood pressure: a systematic review and metaanalysis. J Clin Hypertens (Greenwich). 2013;15:435-42.

  29. Borgi L, McMullan C, Wohlhueter A, Curhan GC, Fisher ND, Forman JP, et al. Effect of uric acid lowering agents on endothelial function: A randomized, double-blind, placebo-controlled trial. Hypertension. 2017;69(2):243-8.

  30. Tayeh MA, Marletta MA. Macrophage oxidation of L-arginine to nitric oxide, nitrite, and nitrate. Tetrahydrobiopterin is required as a cofactor. J Biol Chem. 1989;264:19654-8.

  31. Kanbay M, Jensen T, Solak Y, Le M, Roncal-Jimenez C, Rivard C, et al. Uric acid in metabolic syndrome. From an innocent bystander to a central player. Eur J Intern Med. 2016;29:3-8.

  32. Hoehn KL, Salmon AB, Hohnen-Behrens C, Turner N, Hoy AJ, Maghzal GJ, et al. Insulin resistance is a cellular antioxidant defense mechanism. Proc Natl Acad Sci USA. 2009;106(42):17787-92.

  33. Evans JL, Maddux BA, Goldfine ID. The molecular basis for oxidative stress-induced insulin resistance. Antioxid Redox Signal. 2005 Jul-Aug;7(7-8):1040-52.

  34. Zhu Y, Hu Y, Huang T, Zhang Y, Li Z, Luo C, et al. High uric acid directly inhibits insulin signalling and induces insulin resistance. Biochem Biophys Res Commun. 2014;447:707-14.

  35. Xu YL, Xu XF, Bai JL, Liu Y, Yu RB, Liu CL, et al. Elevation of serum uric acid and incidence of type 2 diabetes: A systematic review and meta-analysis. Chronic Dis Translational Medic. 2016; 2:81-91.

  36. Bjornstad P, Snell-Bergeon JK, McFann K, Wadwa RP, Rewers M, Rivard CJ, et al. Serum uric acid and insulin sensitivity in adolescents and adults with and without type 1 diabetes. J Diabetes Complications. 2014;28(3):298-304.

  37. Chien KL, Chen MF, Hsu HC. Plasma uric acid and the risk of type 2 diabetes in a Chinese community. Clin Chem. 2008;54(2):310-6.

  38. Takir M, Kostek O, Ozkok A, Elcioglu OC, Bakan A, Erek A, et al. Lowering uric acid with allopurinol improves insulin resistance and systemic inflammation in asymptomatic hyperuricemia. J Investig Med. 2015;63(8):924-9.

  39. Babio N, Martínez-González MA, Estruch R, Wärnberg J, Recondo J, Ortega-Calvo M, et al. Associations between serum uric acid concentrations and metabolic syndrome and its components in the PREDIMED study. Nutr Metab Cardiovasc Dis. 2015;25(2):173-80.

  40. Bonakdaran S, Kharaqani B. Association of serum uric acid and metabolic syndrome in type 2 diabetes. Curr Diab Rev. 2014;10(2):113-7.

  41. Moulin SR, Baldo MP, Souza JB, Luchi WM, Capingana DP, Magalhães P, et al. Distribution of serum uric acid in black africans and its association with cardiovascular risk factors. J Clin Hypertens (Greenwich). 2017;19(1):45-50.

  42. 42.Yadav D, Lee ES, Kim HM, Choi E, Lee EY, Lim JS, et al. Prospective study of serum uric acid levels and incident metabolic syndrome in a Korean rural cohort. Atherosclerosis. 2015;241(1):271-7.

  43. Sun HL, Pei D, Lue KH, Chen YL. Uric acid levels can predict metabolic syndrome and hypertension in adolescents: a 10-year longitudinal study. PLoS ONE. 2015;10(11):e0143786.

  44. Li LX, Dongb XH, Lia MF, Zhanga R, Lia TT, Shena J, et al. Serum uric acid levels are associated with hypertension and metabolic syndrome but not atherosclerosis in Chinese patients with type 2 diabetes. J Hypertens. 2015;33:482-90.

  45. Spiga R, Marini MA, Mancuso E, Di Fatta C, Fuoco A, Perticone F, et al. Uric acid is associated with inflammatory biomarkers and induces inflammation via activating the NF-κB signaling pathway in HepG2 Cells. Arterioscler Thromb Vasc Biol. 2017. doi: 10.1161/ATVBAHA.117.309128

  46. Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension. 2003;41:1287-93.

  47. Liang WY, Zhu XY, Zhang JW, Feng XR, Wang YC, Liu ML, et al. Uric acid promotes chemokine and adhesion molecule production in vascular endothelium via nuclear factor-kappa B signaling. Nutr Metab Cardiovasc Dis. 2015;25(2):187-94.

  48. Tanaka T, Milaneschi Y, Zhang Y, Becker KG, Zukley L, Ferrucci L, et al. A double blind pacebo controlled randomized trial of the effect of acute uric acid changes on inflammatory markers in humans: A pilot study. PLoS ONE. 2017; acceso 02/04/2018;12(8):e0181100. Available from: https:// https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546625/pdf/pone.0181100.pdf

  49. Nieto FJ, Iribarren C, Gross MD, Cosmotock GW, Cutler RG. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis. 2000;148:131-9.

  50. Iribarren C, Folsom AR, Eckfeldt JH. Correlates of uric acid and its association with asymptomatic carotid atherosclerosis: the ARIC Study. Atherosclerosis risk in communities. Ann Epidemiol. 1996;6:331-40.

  51. Hannawi S, Al Salmi I, Moller I, Naredo E. Uric acid is independent cardiovascular risk factor, as manifested by increased carotid intima-media thickness in rheumatoid arthritis patients. Clin Rheumatol. 2017;36:1897-902.

  52. Sinan Deveci O, Kabakci G, Okutucu S, Tulumen E, Aksoy H, Baris Kaya E, et al. The association between serum uric acid level and coronary artery disease. Int J Clin Pract. 2010;64(7):900-7.

  53. Duran M, Kalay N, Akpek M, Orscelik O, Elcik D, Ocak A, et al. High levels of serum uric acid predict severity of coronary artery disease in patients with acute coronary syndrome. Angiology. 2012;63(6):448-52.

  54. Céspedes E. Ácido úrico y estrés oxidativo en hipertensos con Cardiopatía isquémica. Tesis para optar por el Título de Máster en Investigaciones en Aterosclerosis. CIRAH 2012.

  55. Paul BJ, Anoopkumar K, Krishnan V. Asymptomatic hyperuricemia: is it time to intervene? Clin Rheumatol. 2017;36:2637-44.

  56. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999;131:7-13.

  57. Tsai TH, Chen YL, Chen SM, Yang CH, Fang CY, Hsieh YK, et al. Uric Acid is not an independent predictor of cardiovascular death in patients with angiographically proven coronary artery disease. Chang Gung Med J. 2009;32(6):605-13.

  58. Keenan T, Zhao W, Rasheed A. Causal assessment of serum urate levels in cardiometabolic diseases through a Mendelian randomization study. J Am Coll Cardiol. 2016;67:407-16.




2020     |     www.medigraphic.com